Etiology of myasthenia gravis: Innate immunity signature in pathological thymus

Autoimmunity Reviews

Volumn 12, Issue 9, 2013, Pages 863-874

  Cavalcante, Paola ^a   Cufi, Perrine ^b   Mantegazza, Renato ^a   Berrih Aknin, Sonia ^b   Bernasconi, Pia ^a   Le Panse, Rozen ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Etiology; Inflammation; Myasthenia gravis; Thymus; Toll like receptors; Viral infection

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERFERON; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; INTERLEUKIN 5; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROTEIN KINASE R; RETINOIC ACID RECEPTOR; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

3' UNTRANSLATED REGION; ADAPTIVE IMMUNITY; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; COMPLEMENT ACTIVATION; CROSS REACTION; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HAPLOTYPE; HEREDITY; HLA SYSTEM; HOMOZYGOSITY; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENICITY; PHENOTYPE; PROMOTER REGION; PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SOMATIC HYPERMUTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMOMA; THYMUS; THYMUS HYPERPLASIA; UPREGULATION; VIRUS INFECTION; X CHROMOSOME INACTIVATION;

ANIMALS; HUMANS; IMMUNITY, INNATE; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; RECEPTORS, CHOLINERGIC; THYMUS GLAND; TOLL-LIKE RECEPTORS;

EID: 84879167018     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.010     Document Type: Review

References (166)

1. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002, 2:797-804.
2. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
3. Jacob S., Viegas S., Leite M.I., Webster R., Cossins J., Kennett R., et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 2012, 69:994-1001.
4. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
5. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
6. Sanders D.B., El-Salem K., Massey J.M., McConville J., Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003, 60:1978-1980.
7. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004, 55:580-584.
8. Evoli A., Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 2013, 12:931-935. (this issue).
9. Mori S., Shigemoto K. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Autoimmun Rev 2013, 12:912-917. (this issue).
10. Zisimopoulou P., Brenner T., Trakas N., Tzartos S.J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013, 12:924-930. (this issue).
11. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012, 69:445-451.
12. Pevzner A., Schoser B., Peters K., Cosma N.C., Karakatsani A., Schalke B., et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012, 259:427-435.
13. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
14. Mantegazza R., Baggi F., Antozzi C., Confalonieri P., Morandi L., Bernasconi P., et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 2003, 998:413-423.
15. Heldal A.T., Owe J.F., Gilhus N.E., Romi F. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology 2009, 73:150-151.
16. Aragones J.M., Bolibar I., Bonfill X., Bufill E., Mummany A., Alonso F., et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003, 60:1024-1026.
17. Meyer A., Levy Y. Geoepidemiology of myasthenia gravis. Autoimmun Rev 2010, 9:A383-A386. [corrected].
18. Drachman D.B., Adams R.N., Josifek L.F., Self S.G. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982, 307:769-775.
19. Vincent A., McConville J., Farrugia M.E., Newsom-Davis J. Seronegative myasthenia gravis. Semin Neurol 2004, 24:125-133.
20. Müller-Hermelink H.K., Marx A., Geuder K.I., Kirchner T. Thymus. Anderson's Pathology 1996, 1218-1243. Mosby, Saint Louis. I. Damjanov, J. Linder (Eds.).
21. Berrih-Aknin S., Le Ragheb S., Panse R., Lisak R.P. Ectopic germinal centers, BAFF and anti-B cell therapy in myasthenia gravis. Autoimmun Rev 2013, 12:885-893. (this issue).
22. Patrick J., Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973, 180:871-872.
23. Dalakas M.C. Novel future therapeutic options in Myasthenia Gravis. Autoimmun Rev 2013, 12:936-941. (this issue).
24. Murphy J., Murphy S.F. Myasthenia gravis in identical twins. Neurology 1986, 36:78-80.
25. Vandiedonck C., Giraud M., Garchon H.J. Genetics of autoimmune myasthenia gravis: the multifaceted contribution of the HLA complex. J Autoimmun 2005, 25(Suppl.):6-11.
26. Degli-Esposti M.A., Andreas A., Christiansen F.T., Schalke B., Albert E., Dawkins R.L. An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes. Immunogenetics 1992, 35:355-364.
27. Perricone C., Ceccarelli F., Valesini G. An overview on the genetic of rheumatoid arthritis: a never-ending story. Autoimmun Rev 2011, 10:599-608.
28. Borchers A.T., Naguwa S.M., Shoenfeld Y., Gershwin M.E. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010, 9:A277-A287.
29. Christensen P.B., Jensen T.S., Tsiropoulos I., Sorensen T., Kjaer M., Hojer-Pedersen E., et al. Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurol Scand 1995, 91:192-195.
30. Baggi F., Antozzi C., Andreetta F., Confalonieri P., Ciusani E., Begovich A.B., et al. Identification of a novel HLA class II association with DQB1*0502 in an Italian myasthenic population. Ann N Y Acad Sci 1998, 841:355-359.
31. Deitiker P.R., Oshima M., Smith R.G., Mosier D., Atassi M.Z. Association with HLA DQ of early onset myasthenia gravis in Southeast Texas region of the United States. Int J Immunogenet 2011, 38:55-62.
32. Lio D., Candore G., Romano G.C., D'Anna C., Gervasi F., Di Lorenzo G., et al. Modification of cytokine patterns in subjects bearing the HLA-B8, DR3 phenotype: implications for autoimmunity. Cytokines Cell Mol Ther 1997, 3:217-224.
33. Maniaol A.H., Elsais A., Lorentzen A.R., Owe J.F., Viken M.K., Saether H., et al. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 2012, 7:e36603.
34. Niks E.H., Kuks J.B., Roep B.O., Haasnoot G.W., Verduijn W., Ballieux B.E., et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006, 66:1772-1774.
35. Bartoccioni E., Scuderi F., Augugliaro A., Chiatamone Ranieri S., Sauchelli D., Alboino P., et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009, 72:195-197.
36. Vieira M.L., Caillat-Zucman S., Gajdos P., Cohen-Kaminsky S., Casteur A., Bach J.F. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J Neuroimmunol 1993, 47:115-122.
37. Vandiedonck C., Raffoux C., Eymard B., Tranchant C., Dulmet E., Krumeich S., et al. Association of HLA-A in autoimmune myasthenia gravis with thymoma. J Neuroimmunol 2009, 210:120-123.
38. Yang H., Hao J., Peng X., Simard A.R., Zhang M., Xie Y., et al. The association of HLA-DQA1*0401 and DQB1*0604 with thymomatous myasthenia gravis in northern Chinese patients. J Neurol Sci 2012, 312:57-61.
39. Skeie G.O., Pandey J.P., Aarli J.A., Gilhus N.E. TNFA and TNFB polymorphisms in myasthenia gravis. Arch Neurol 1999, 56:457-461.
40. Huang D.R., Pirskanen R., Matell G., Lefvert A.K. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis. J Neuroimmunol 1999, 94:165-171.
41. Wang H.B., Li H., Shi F.D., Chambers B.J., Link H., Ljunggren H.G. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int Immunol 2000, 12:1381-1388.
42. Wang X.B., Pirskanen R., Giscombe R., Lefvert A.K. Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med 2008, 263:61-69.
43. Yilmaz V., Tutuncu Y., Baris Hasbal N., Parman Y., Serdaroglu P., Deymeer F., et al. Polymorphisms of interferon-gamma, interleukin-10, and interleukin-12 genes in myasthenia gravis. Hum Immunol 2007, 68:544-549.
44. Burn G.L., Svensson L., Sanchez-Blanco C., Saini M., Cope A.P. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?. FEBS Lett 2011, 585:3689-3698.
45. Giraud M., Vandiedonck C., Garchon H.J. Genetic factors in autoimmune myasthenia gravis. Ann N Y Acad Sci 2008, 1132:180-192.
46. Gregersen P.K., Lee H.S., Batliwalla F., Begovich A.B. PTPN22: setting thresholds for autoimmunity. Semin Immunol 2006, 18:214-223.
47. Gianchecchi E., Palombi M., Fierabracci A. The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity. Autoimmun Rev 2012 Dec 20, [pii: S1568-9972(12)00294-7. doi: http://dx.doi.org/10.1016/j.autrev.2012.12.003. [Epub ahead of print]].
48. Menard L., Saadoun D., Isnardi I., Ng Y.S., Meyers G., Massad C., et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest 2011, 121:3635-3644.
49. Zhang J., Zahir N., Jiang Q., Miliotis H., Heyraud S., Meng X., et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 2011, 43:902-907.
50. Vandiedonck C., Capdevielle C., Giraud M., Krumeich S., Jais J.P., Eymard B., et al. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 2006, 59:404-407.
51. Provenzano C., Ricciardi R., Scuderi F., Maiuri M.T., Maestri M., La Carpia F., et al. PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data. Neuromuscul Disord 2012, 22:131-138.
52. Chuang W.Y., Strobel P., Belharazem D., Rieckmann P., Toyka K.V., Nix W., et al. The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. Genes Immun 2009, 10:667-672.
53. Giraud M., Taubert R., Vandiedonck C., Ke X., Levi-Strauss M., Pagani F., et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007, 448:934-937.
54. Lettre G., Rioux J.D. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet 2008, 17:R116-R121.
55. Hystad M.E., Myklebust J.H., Bo T.H., Sivertsen E.A., Rian E., Forfang L., et al. Characterization of early stages of human B cell development by gene expression profiling. J Immunol 2007, 179:3662-3671.
56. Cheung Y.H., Watkinson J., Anastassiou D. Conditional meta-analysis stratifying on detailed HLA genotypes identifies a novel type 1 diabetes locus around TCF19 in the MHC. Hum Genet 2011, 129:161-176.
57. Zhang J., Chen Y., Shao Y., Wu Q., Guan M., Zhang W., et al. Identification of TNIP1 polymorphisms by high resolution melting analysis with unlabelled probe: association with systemic lupus erythematosus. Autoimmun Dis 2012, 2012:265823.
58. Bowes J., Orozco G., Flynn E., Ho P., Brier R., Marzo-Ortega H., et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 2011, 70:1641-1644.
59. Ramirez V.P., Gurevich I., Aneskievich B.J. Emerging roles for TNIP1 in regulating post-receptor signaling. Cytokine Growth Factor Rev 2012, 23:109-118.
60. Nanda S.K., Venigalla R.K., Ordureau A., Patterson-Kane J.C., Powell D.W., Toth R., et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J Exp Med 2011, 208:1215-1228.
61. Landoure G., Knight M.A., Stanescu H., Taye A.A., Shi Y., Diallo O., et al. A candidate gene for autoimmune myasthenia gravis. Neurology 2012, 79:342-347.
62. Anaya J.-M. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev 2012, 11:781-784.
63. Nussinovitch U., Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev 2012, 11:A377-A385.
64. Le Panse R., Cizeron-Clairac G., Cuvelier M., Truffault F., Bismuth J., Nancy P., et al. Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis. Ann N Y Acad Sci 2008, 1132:135-142.
65. Oertelt-Prigione S. The influence of sex and gender on the immune response. Autoimmun Rev 2012, 11:A479-A485.
66. Delpy L., Douin-Echinard V., Garidou L., Bruand C., Saoudi A., Guery J.C. Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. J Immunol 2005, 175:5050-5057.
67. Kawashima I., Seiki K., Sakabe K., Ihara S., Akatsuka A., Katsumata Y. Localization of estrogen receptors and estrogen receptor-mRNA in female mouse thymus. Thymus 1992, 20:115-121.
68. Nancy P., Berrih-Aknin S. Differential estrogen receptor expression in autoimmune myasthenia gravis. Endocrinology 2005, 146:2345-2353.
69. Selmi C., Brunetta E., Raimondo M., Meroni P. The X chromosome and the sex ratio of autoimmunity. Autoimmun Rev 2012, 11:A532-A537.
70. Penn A.S., Low B.W., Jaffe I.A., Luo L., Jacques J.J. Drug-induced autoimmune myasthenia gravis. Ann N Y Acad Sci 1998, 841:433-449.
71. Poulas K., Koutsouraki E., Kordas G., Kokla A., Tzartos S.J. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol 2012, 250:94-98.
72. Stubgen J.P. Interferon alpha and neuromuscular disorders. J Neuroimmunol 2009, 207:3-17.
73. Cufi P., Dragin N., Weiss J.M., Martinez-Martinez P., Roussin R., Berrih Aknin S., et al. Implication of dsRNA signaling in the etiology of autoimmune myasthenia gravis. Ann Neurol 2013, 73:281-293.
74. Bogdanos D.P., Smyk D.S., Invernizzi P., Rigopoulou E.I., Blank M., Pouria S., et al. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev 2012, 10.1016/j.autrev.2012.12.005.
75. Askmark H., Haggard L., Nygren I., Punga A.R. Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3: a pilot study. Eur J Neurol 2012, 19:1554-1560.
76. Simon K.C., Munger K.L., Ascherio A. Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Curr Opin Neurol 2012, 25:246-251.
77. Antico A., Tampoia M., Tozzoli R., Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 2012, 12:127-136.
78. Munz C., Lunemann J.D., Getts M.T., Miller S.D. Antiviral immune responses: triggers of or triggered by autoimmunity?. Nat Rev Immunol 2009, 9:246-258.
79. Bach J.F. Infections and autoimmune diseases. J Autoimmun 2005, 25 Suppl.:74-80.
80. Temajo N.O., Howard N. The viral enterprises in autoimmunity: conversion of target cells into de novo APCs is the presage to autoimmunity. Autoimmun Rev 2012, 11:653-658.
81. Leite M.I., Strobel P., Jones M., Micklem K., Moritz R., Gold R., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448.
82. Lauriola L., Ranelletti F., Maggiano N., Guerriero M., Punzi C., Marsili F., et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 64:536-538.
83. Marx A., Willcox N., Leite M.I., Chuang W.Y., Schalke B., Nix W., et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010, 43:413-427.
84. Rosai J., Sobin L.H. Histological typing of tumors of the thymus. International Histological Classification of Tumors 1999, Springer, New York. W.H. Organization (Ed.).
85. Maggi L., Andreetta F., Antozzi C., Baggi F., Bernasconi P., Cavalcante P., et al. Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. J Neuroimmunol 2008, 201-202:237-244.
86. Strobel P., Chuang W.Y., Chuvpilo S., Zettl A., Katzenberger T., Kalbacher H., et al. Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann N Y Acad Sci 2008, 1132:143-156.
87. Savino W., Manganella G., Verley J.M., Wolff A., Berrih S., Levasseur P., et al. Thymoma epithelial cells secrete thymic hormone but do not express class II antigens of the major histocompatibility complex. J Clin Invest 1985, 76:1140-1146.
88. Scarpino S., Di Napoli A., Stoppacciaro A., Antonelli M., Pilozzi E., Chiarle R., et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 2007, 149:504-512.
89. Cavalcante P., Le Panse R., Berrih-Aknin S., Maggi L., Antozzi C., Baggi F., et al. The thymus in myasthenia gravis: site of "innate autoimmunity"?. Muscle Nerve 2011, 44:467-484.
90. Le Panse R., Cizeron-Clairac G., Bismuth J., Berrih Aknin S. Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CCL21 in thymic hyperplasia. J Immunol 2006, 177:7868-7879.
91. Cizeron-Clairac G., Le Panse R., Frenkian-Cuvelier M., Méraouna A., Truffault F., Bismuth J., et al. Thymus and myasthenia gravis: what can we learn from DNA microarrays?. J Neuroimmunol 2008, 201-202:57-63.
92. Sims G.P., Shiono H., Willcox N., Stott D.I. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 2001, 167:1935-1944.
93. McLachlan S.M., Nicholson L.V., Venables G., Mastalgia F.L., Bates D., Smith B.R., et al. Acetylcholine receptor antibody synthesis in lymphocyte cultures. J Clin Lab Immunol 1981, 5:137-142.
94. Schluep M., Willcox N., Vincent A., Dhoot G.K., Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol 1987, 22:212-222.
95. Mesnard-Rouiller L., Bismuth J., Wakkach A., Poëa-Guyon S., Berrih-Aknin S. Thymic myoid cells express high levels of muscle genes. J Neuroimmunol 2004, 148:97-105.
96. Wakkach A., Guyon T., Bruand C., Tzartos S., Cohen-Kaminsky S., Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J Immunol 1996, 157:3752-3760.
97. Leite M.I., Jones M., Strobel P., Marx A., Gold R., Niks E., et al. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007, 171:893-905.
98. Melms A., Schalke B.C., Kirchner T., Müller-Hermelink H.K., Albert E., Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest 1988, 81:902-908.
99. Hill M.E., Shiono H., Newsom-Davis J., Willcox N. The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics. J Neuroimmunol 2008, 201-202:50-56.
100. Berrih-Aknin S., Morel E., Raimond F., Safar D., Gaud C., Binet J., et al. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. Ann N Y Acad Sci 1987, 505:50-70.
101. Safar D., Berrih-Aknin S., Morel E. In vitro anti-acetylcholine receptor antibody synthesis by myasthenia gravis patient lymphocytes: correlations with thymic histology and thymic epithelial-cell interactions. J Clin Immunol 1987, 7:225-234.
102. Schonbeck S., Padberg F., Hohlfeld R., Wekerle H. Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis. J Clin Invest 1992, 90:245-250.
103. Mantegazza R., Baggi F., Bernasconi P., Antozzi C., Confalonieri P., Novellino L., et al. Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6years of follow-up. J Neurol Sci 2003, 212:31-36.
104. Gronseth G.S., Barohn R.J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:7-15.
105. Okumura M., Ohta M., Takeuchi Y., Shiono H., Inoue M., Fukuhara K., et al. The immunologic role of thymectomy in the treatment of myasthenia gravis: implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer. J Thorac Cardiovasc Surg 2003, 126:1922-1928.
106. Mori T., Nomori H., Ikeda K., Kobayashi H., Iwatani K., Kobayashi T. The distribution of parenchyma, follicles, and lymphocyte subsets in thymus of patients with myasthenia gravis, with special reference to remission after thymectomy. J Thorac Cardiovasc Surg 2007, 133:364-368.
107. Méraouna A., Cizeron-Clairac G., Le Panse R., Bismuth J., Truffault F., Talaksen C., et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006, 108:432-440.
108. Berrih-Aknin S., Ruhlmann N., Bismuth J., Cizeron-Clairac G., Zelman E., Shachar I., et al. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. Ann Neurol 2009, 66:521-531.
109. Feferman T., Maiti P.K., Berrih-Aknin S., Bismuth J., Bidault J., Fuchs S., et al. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol 2005, 174:5324-5331.
110. Weiss J.M., Cufi P., Bismuth J., Eymard B., Fadel E., Berrih-Aknin S., et al. SDF-1/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients. Immunobiology 2013, 218:373-381.
111. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003, 132:128-136.
112. Willcox N., Leite M.I., Kadota Y., Jones M., Meager A., Subrahmanyam P., et al. Autoimmunizing mechanisms in thymoma and thymus. Ann N Y Acad Sci 2008, 1132:163-173.
113. de Weerd N.A., Nguyen T. The interferons and their receptors-distribution and regulation. Immunol Cell Biol 2012, 90:483-491.
114. Gu D., Wogensen L., Calcutt N.A., Xia C., Zhu S., Merlie J.P., et al. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J Exp Med 1995, 181:547-557.
115. Balasa B., Deng C., Lee J., Bradley L.M., Dalton D.K., Christadoss P., et al. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med 1997, 186:385-391.
116. Zhang G.X., Xiao B.G., Bai X.F., van der Meide P.H., Orn A., Link H. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol 1999, 162:3775-3781.
117. Poëa-Guyon S., Christadoss P., Le Panse R., Guyon T., De Baets M., Wakkach A., et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol 2005, 174:5941-5949.
118. Chang J.H., Kim Y.J., Han S.H., Kang C.Y. IFN-gamma-STAT1 signal regulates the differentiation of inducible Treg: potential role for ROS-mediated apoptosis. Eur J Immunol 2009, 39:1241-1251.
119. Meloni A., Furcas M., Cetani F., Marcocci C., Falorni A., Perniola R., et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2008, 93:4389-4397.
120. Golding A., Rosen A., Petri M., Akhter E., Andrade F. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology 2008, 131:107-117.
121. Onoguchi K., Yoneyama M., Takemura A., Akira S., Taniguchi T., Namiki H., et al. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007, 282:7576-7581.
122. Sommereyns C., Paul S., Staeheli P., Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008, 4:e1000017.
123. Janeway C.A., Travers P., Walport M., Capra J.D. Principals of innate and adaptive immunity. Immunobiology: the Immune System in Health and Disease 2001, 11-20. Garland Sci, New York. C.A. Janeway, P. Travers (Eds.).
124. Hoebe K., Janssen E., Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004, 5:971-974.
125. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
126. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
127. Hurst J., von Landenberg P. Toll-like receptors and autoimmunity. Autoimmun Rev 2008, 7:204-208.
128. Pisetsky D.S. The role of innate immunity in the induction of autoimmunity. Autoimmun Rev 2008, 8:69-72.
129. Lien E., Zipris D. The role of Toll-like receptor pathways in the mechanism of type 1 diabetes. Curr Mol Med 2009, 9:52-68.
130. Shotorbani S.S., Su Z.L., Xu H.X. Toll-like receptors are potential therapeutic targets in rheumatoid arthritis. World J Biol Chem 2011, 2:167-172.
131. Gambuzza M., Licata N., Palella E., Celi D., Foti Cuzzola V., Italiano D., et al. Targeting Toll-like receptors: emerging therapeutics for multiple sclerosis management. J Neuroimmunol 2011, 239:1-12.
132. Tzartos J.S., Khan G., Vossenkamper A., Cruz-Sadaba M., Lonardi S., Sefia E., et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012, 78:15-23.
133. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007, 204:2899-2912.
134. Crampton S.P., Voynova E., Bolland S. Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci 2010, 1183:58-68.
135. Green N.M., Moody K.S., Debatis M., Marshak-Rothstein A. Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands. J Biol Chem 2012, 287:39789-39799.
136. Meyer-Bahlburg A., Rawlings D.J. B cell autonomous TLR signaling and autoimmunity. Autoimmun Rev 2008, 7:313-316.
137. Green N.M., Marshak-Rothstein A. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol 2011, 23:106-112.
138. Miles K., Heaney J., Sibinska Z., Salter D., Savill J., Gray D., et al. A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. Proc Natl Acad Sci U S A 2012, 109:887-892.
139. Hackl D., Loschko J., Sparwasser T., Reindl W., Krug A.B Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur J Immunol 2011, 1334-1343.
140. Colonna M. Toll-like receptors and IFN-alpha: partners in autoimmunity. J Clin Invest 2006, 116:2319-2322.
141. Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol 2006, 91:159-173.
142. Wang Y.Z., Yan M., Tian F.F., Zhang J.M., Liu Q., Yang H., et al. Possible involvement of Toll-like receptors in the pathogenesis of myasthenia gravis. Inflammation 2013, 36:121-130.
143. Savino W. The thymus is a common target organ in infectious diseases. PLoS Pathog 2006, 2:e62.
144. Bernasconi P., Barberis M., Baggi F., Passerini L., Cannone M., Arnoldi E., et al. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol 2005, 167:129-139.
145. Fujinami R.S., Oldstone M.B. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985, 230:1043-1045.
146. Korn I.L., Abramsky O. Myasthenia gravis following viral infection. Eur Neurol 1981, 20. [435-9U].
147. Bhibhatbhan A., Kline G., Vincent A., Toth C. Anti-MuSK myasthenia gravis presenting with Epstein-Barr virus-associated mononucleosis and immune-mediated diabetes mellitus. Muscle Nerve 2007, 36:264-266.
148. Verma A., Berger J. Myasthenia gravis associated with dual infection of HIV and HTLV-I. Muscle Nerve 1995, 18:1355-1356.
149. Schwimmbeck P.L., Dyrberg T., Drachman D.B., Oldstone M.B. Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 1989, 84:1174-1180.
150. Stefansson K., Dieperink M.E., Richman D.P., Gomez C.M., Marton L.S. Sharing of antigenic determinants between the nicotinic acetylcholine receptor and proteins in Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae. Possible role in the pathogenesis of myasthenia gravis. N Engl J Med 1985, 312:221-225.
151. Tindall R.S., Cloud R., Luby J., Rosenberg R.N. Serum antibodies to cytomegalovirus in myasthenia gravis: effects of thymectomy and steroids. Neurology 1978, 28:273-277.
152. Klavinskis L.S., Willcox N., Oxford J.S., Newsom-Davis J. Antivirus antibodies in myasthenia gravis. Neurology 1985, 35:1381-1384.
153. Csuka D., Banati M., Rozsa C., Fust G., Illes Z. High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis. Eur J Neurol 2012, 19:842-846.
154. Ascherio A., Munger K.L., Lennette E.T., Spiegelman D., Hernan M.A., Olek M.J., et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001, 286:3083-3088.
155. Aoki T., Drachman D.B., Asher D.M., Gibbs C.J., Bahmanyar S., Wolinsky J.S. Attempts to implicate viruses in myasthenia gravis. Neurology 1985, 35:185-192.
156. Klavinskis L.S., Willcox H.N., Richmond J.E., Newsom-Davis J. Attempted isolation of viruses from myasthenia gravis thymus. J Neuroimmunol 1986, 11:287-299.
157. McGuire L.J., Huang D.P., Teoh R., Arnold M., Wong K., Lee J.C. Epstein-Barr virus genome in thymoma and thymic lymphoid hyperplasia. Am J Pathol 1988, 131:385-390.
158. Cavalcante P., Barberis M., Cannone M., Baggi F., Antozzi C., Maggi L., et al. Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis. Neurology 2010, 74:1118-1126.
159. Cavalcante P., Serafini B., Rosicarelli B., Maggi L., Barberis M., Antozzi C., et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010, 67:726-738.
160. Niller H.H., Wolf H., Ay E., Minarovits J. Epigenetic dysregulation of Epstein-Barr virus latency and development of autoimmune disease. Adv Exp Med Biol 2011, 711:82-102.
161. Cavalcante P., Maggi L., Colleoni L., Caldara R., Motta T., Giardina C., et al. Inflammation and Epstein-Barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis. Autoimmun Dis 2011, 2011:213092.
162. Iwakiri D., Zhou L., Samanta M., Matsumoto M., Ebihara T., Seya T., et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009, 206:2091-2099.
163. Ning S. Innate immune modulation in EBV infection. Herpesviridae 2011, 2:1.
164. Kakalacheva K., Maurer M.A., Tackenberg B., Munz C., Willcox N., Lunemann J.D. Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis. Ann Neurol 2011, 70:508-514.
165. Meyer M., Hols A.K., Liersch B., Leistner R., Gellert K., Schalke B., et al. Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus. Ann Neurol 2011, 70:515-518.
166. Serafini B., Cavalcante P., Bernasconi P., Aloisi F., Mantegazza R. Epstein-Barr virus in myasthenia gravis thymus: a matter of debate. Ann Neurol 2011, 70:519.